This is an open-label, nonrandomized phase I trial to determine the safety and maximum tolerated dose of irinotecan with a fixed dose of UFT plus oral leucovorin in patients with advanced or metastatic colorectal cancer.
Dieter Kurt Hossfeld, MD, PhD
Advertisement
Articles by Dieter Kurt Hossfeld, MD, PhD
Advertisement
Latest Updated Articles
- UFT/Leucovorin Plus Weekly Irinotecan in Advanced or Metastatic Colorectal Cancer
Published: October 1st 2000 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Could Scorpion Venom Component Play a Role in Glioblastoma Management?
2
Evaluating the Viability of Antibody Drug Conjugates for Glioblastoma
3
FDA Approves Abbreviated NDA for Dasatinib Tablets in Leukemia Indications
4
How Dato-DXd and the TROPION Trials Are Transforming Solid Tumor Research
5
